In vivo activity of the second-generation proteasome inhibitor ixazomib against pediatric t-cell acute lymphoblastic leukemia xenografts

While overall survival rates for pediatric acute lymphoblastic leukemia (ALL) are approximately 90%, patients with relapsed T-cell ALL (T-ALL) have a particularly poor prognosis.1 Therefore, there is an urgent need to develop novel therapies that target relapsed/refractory ALL. The ubiquitin-proteasome system (UPS) maintains normal protein homeostasis and is responsible for a host of cellular processes including intracellular protein degradation, apoptosis, inflammation, and cell cycle control.2 Dysregulation of UPS-controlled processes has been linked to many cancers, rendering the UPS an attractive therapeutic target leading to the development of proteasome inhibitors.

Source: Experimental Hematology - February 4, 2024 Category: Hematology Authors: Joanna Randall, Kathryn Evans, Ben Watts, Hansen J. Kosasih, Christopher M. Smith, Eric J. Earley, Stephen W. Erickson, Emily L. Jocoy, Carol J. Bult, Beverly A. Teicher, Charles E. de Bock, Malcolm A. Smith, Richard B. Lock Tags: Brief Communication Source Type: research